Correlation Between Puma Biotechnology and Onconetix

Can any of the company-specific risk be diversified away by investing in both Puma Biotechnology and Onconetix at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Puma Biotechnology and Onconetix into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Puma Biotechnology and Onconetix, you can compare the effects of market volatilities on Puma Biotechnology and Onconetix and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Puma Biotechnology with a short position of Onconetix. Check out your portfolio center. Please also check ongoing floating volatility patterns of Puma Biotechnology and Onconetix.

Diversification Opportunities for Puma Biotechnology and Onconetix

-0.5

Correlation Coefficient

Puma Biotechnology  Onconetix

Very good diversification

The 3 months correlation between Puma and Onconetix is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Puma Biotechnology and Onconetix in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Onconetix and Puma Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Puma Biotechnology are associated (or correlated) with Onconetix. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Onconetix has no effect on the direction of Puma Biotechnology i.e., Puma Biotechnology and Onconetix go up and down completely randomly.

Pair Corralation between Puma Biotechnology and Onconetix

Given the investment horizon of 90 days Puma Biotechnology is expected to generate 0.42 times more return on investment than Onconetix. However, Puma Biotechnology is 2.39 times less risky than Onconetix. It trades about 0.02 of its potential returns per unit of risk. Onconetix is currently generating about -0.16 per unit of risk. If you would invest  313.00  in Puma Biotechnology on December 28, 2024 and sell it today you would earn a total of  2.00  from holding Puma Biotechnology or generate 0.64% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	98.36%
Values	Daily Returns

Puma Biotechnology  vs.  Onconetix

Puma Biotechnology

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Onconetix

Risk-Adjusted Performance

Very Weak

Over the last 90 days Onconetix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Puma Biotechnology and Onconetix

The main advantage of trading using opposite Puma Biotechnology and Onconetix positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Puma Biotechnology position performs unexpectedly, Onconetix can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will offset losses from the drop in Onconetix's long position.

The idea behind Puma Biotechnology and Onconetix pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.